My thoughts are only vague. The more qualified SI biofreaks shun gene therapy companies, but, while I do not currently own any, my Mom owns three on my recommendation: INGN, GNVC, and CEGE. If one of these can break through the skittishness of the FDA over gene therapy -- and that of investors -- and get a product on the market, the rest will benefit. Obviously, INGN and CEGE are at the forefront. The stocks have been so underappreciated relative to say, VEGF companies, for so long, that even I began to doubt the near and intermediate term and traded out of them, looking for a pullback. At this point, INGN would be my top pick on a pullback, then CEGE.
Cheers, Tuck |
